Next Article in Journal
The Juggernaut of Adaptive Metabolism in Cancers: Implications and Therapeutic Targets
Next Article in Special Issue
Targeted Therapies and Developing Precision Medicine in Gastric Cancer
Previous Article in Journal
Occupational Exposure to Pesticides Affects Pivotal Immunologic Anti-Tumor Responses in Breast Cancer Women from the Intermediate Risk of Recurrence and Death
Previous Article in Special Issue
The Role of ctDNA in Gastric Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer

by
Thorsten Oliver Goetze
* and
Salah-Eddin Al-Batran
Krankenhaus Nordwest gGmbH, Institut of Clinical Cancer Research, UCT—University Cancer Center Frankfurt-Marburg, Steinbacher Hohl 2-26, 60488 Frankfurt, Germany
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(21), 5200; https://doi.org/10.3390/cancers14215200
Submission received: 20 September 2022 / Revised: 17 October 2022 / Accepted: 21 October 2022 / Published: 23 October 2022

Simple Summary

In metastatic stages of gastric cancer, surgical intervention with curative or life-prolonging intention is still a highly individualized as well as experimental approach, which is unfortunately often performed in daily routines without the sufficient data of well-powered randomized trials. In particular, a small subgroup of metastatic patients showing a limited number of distant metastases in a restricted number of organs, termed limited or oligometastatic disease, needs further evaluation and is discussed in the current manuscript.

Abstract

Gastric adenocarcinoma and esophageal cancer are the fifth and seventh most common cancer types worldwide. At the time of initial diagnosis, up to 50% of esophagogastric cancers present with distant metastatic lesions and are candidates for chemotherapy. Curative surgery in this stage is still an experimental approach. Only a small number of these metastatic patients show an oligometastatic disease with no uniform definition of what oligometastatic means in gastric cancer. Nevertheless, the question remains unanswered as to whether these patients are still candidates for curative concepts. Some studies have attempted to answer this question but have not been adequately designed to address the role of a curative-intended multimodal therapy in this setting. The current FLOT-5 is designed to potentially provide a definitive answer to the question of whether curatively intended surgery plays a role or is a disadvantage in this setting.
Keywords: gastric cancer; gastroesophageal cancer; limited metastatic disease; oligometastatic disease; chemotherapy; immunotherapy; peritoneal carcinomatosis; Peritoneal Cancer Index gastric cancer; gastroesophageal cancer; limited metastatic disease; oligometastatic disease; chemotherapy; immunotherapy; peritoneal carcinomatosis; Peritoneal Cancer Index

Share and Cite

MDPI and ACS Style

Goetze, T.O.; Al-Batran, S.-E. Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer. Cancers 2022, 14, 5200. https://doi.org/10.3390/cancers14215200

AMA Style

Goetze TO, Al-Batran S-E. Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer. Cancers. 2022; 14(21):5200. https://doi.org/10.3390/cancers14215200

Chicago/Turabian Style

Goetze, Thorsten Oliver, and Salah-Eddin Al-Batran. 2022. "Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer" Cancers 14, no. 21: 5200. https://doi.org/10.3390/cancers14215200

APA Style

Goetze, T. O., & Al-Batran, S.-E. (2022). Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer. Cancers, 14(21), 5200. https://doi.org/10.3390/cancers14215200

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop